Drug Profile


Alternative Names: BAY 1192631; DA-70157; DA-70218; DA-7157; DA-7218; SIVEXTRO; Tedizolid phosphate; Torezolid; Torezolid phosphate; TR-700; TR-701; TR-701 FA; TR-701 free acid

Latest Information Update: 20 May 2017

Price : $50

At a glance

  • Originator Dong-A Pharmaceutical
  • Developer Bayer; Dong-A ST; Merck & Co
  • Class Antibacterials; Oxazolidinones; Small molecules
  • Mechanism of Action Ribosomal protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Skin and soft tissue infections
  • Phase III Nosocomial pneumonia
  • Phase I Bacteraemia; Gram-positive infections

Most Recent Events

  • 01 Oct 2016 Bayer completes a phase III trial in Skin and soft tissue infections in Japan (NCT01967225)
  • 01 Apr 2016 Bayer completes a phase III trial in Skin and soft tissue infections in USA, China, Philippines and Taiwan (IV) (NCT02066402)
  • 08 Jan 2016 Phase-I clinical trials in Gram-positive infections (In children) in USA (IV and PO) (EudraCT2015-004595-29)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top